Claims for Patent: 9,895,343

Summary for Patent: 9,895,343

Title:	Method for treating tumors with cannabinoids
Abstract:	A method for treating radiotherapy- or chemotherapy-induced cognitive or emotional impairment by topically administering a cannabinoid. Also provided is a method for treating a tumor by topically administering a cannabinoid together with radiotherapy and/or chemotherapy.
Inventor(s):	Sawyer; Kenneth I. (Cushing, ME), Chang; Wei-wei (Boston, MA)
Assignee:	GLIA, LLC (Boston, MA)
Application Number:	15/170,418
Patent Claims:	1. A method for treating a tumor in a subject, wherein the subject has been diagnosed with a tumor or the subject has had surgery to remove a tumor, the method comprising administering to the subject a chemotherapy agent and/or radiation, and topically administering a composition containing a cannabinoid, wherein the cannabinoid is selected from the group consisting of dronabinol, cannabinol, cannabidiol, .DELTA.9-tetrahydrocannabinol, .DELTA.8-tetrahydrocannabinol, 11-hydroxy-tetrahydrocannabinol, 11-hydroxy-.DELTA.9-tetrahydrocannabinol, levonantradol, .DELTA.11-tetrahydrocannabinol, tetrahydrocannabivarin, anandamide, virodhamine, noladin ester, 2-arachidonoylglycerol, and nabilone; the composition is topically administered to the back of the neck of the subject or to an area of the face of the subject not including the palpebral part of the eye; a dosage of cannabinoid administered topically to the subject is 0.01-30 mg per day; and the tumor is a brain tumor, a nervous system tumor, a head and neck tumor, or an endocrine tumor. 2. The method of claim 1, wherein the cannabinoid is dronabinol or .DELTA.9-tetrahydrocannabinol and the dosage of cannabinoid is 0.1-10 mg per day. 3. A method for treating a tumor in a subject, wherein the subject has been diagnosed with a tumor or the subject has had surgery to remove a tumor, the method comprising administering to the subject a chemotherapy agent and/or radiation, and topically administering a composition containing a cannabinoid, wherein the cannabinoid is dronabinol or .DELTA.9-tetrahydrocannabinol; the composition is topically administered to the back of the neck of the subject or to an area of the face of the subject not including the palpebral part of the eye; the tumor is a brain tumor, a nervous system tumor, a head and neck tumor, or an endocrine tumor; and a dosage of dronabinol or .DELTA.9-tetrahydrocannabinol administered topically to the subject is 0.01-30 mg per day. 4. A method for treating a tumor in a subject, wherein the subject has been diagnosed with a tumor or the subject has had surgery to remove a tumor, the method comprising administering to the subject a chemotherapy agent and/or radiation, and topically administering a composition containing a cannabinoid, wherein the tumor is a glioblastoma and a dosage of cannabinoid administered topically to the subject is 0.01-30 mg per day. 5. The method of claim 4, wherein the composition is topically administered to the back of the neck of the subject or to an area of the face of the subject not including the palpebral part of the eye. 6. A method for treating a tumor in a subject, wherein the subject has been diagnosed with a tumor or the subject has had surgery to remove a tumor, the method comprising administering to the subject a chemotherapy agent and/or radiation, and topically administering a composition containing a cannabinoid, wherein the tumor is a glioblastoma proliferating from a primary tumor after complete or partial extirpation and treatment of the primary tumor or of a secondary tumor. 7. The method of claim 6, wherein the composition is topically administered to the back of the neck of the subject or to an area of the face of the subject not including the palpebral part of the eye. 8. The method of claim 7, wherein the cannabinoid is dronabinol and the dronabinol is administered subsequent to or together with administering a taxane, a platinum compound, a vinca alkaloid, thalidomide, bortezomib, a corticosteroid, topotecan, bevacizumab, temozolamide, etoposide, carboplatin, irinotecan, lomustine, or a combination thereof.

Details for Patent 9,895,343

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2034-07-21